Patents by Inventor Jianmei OUYANG

Jianmei OUYANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
    Patent number: 11419918
    Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: August 23, 2022
    Inventors: Lei Wang, Jianmei Ouyang
  • TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE
    Publication number: 20210187074
    Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.
    Type: Application
    Filed: October 19, 2018
    Publication date: June 24, 2021
    Inventors: Lei WANG, Jianmei OUYANG